Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies
Nadofaragene firadenovec demonstrated a favorable and tolerable safety profile across its clinical study program, allowing for broad patient selection among those with high-risk BCG-unresponsive NMIBC.
Authors
- Yair Lotan (ORCID: https://orcid.org/0000-0001-5692-2723)
- Amanda Myers
- Badrinath R. Konety (ORCID: https://orcid.org/0000-0002-1088-3981)
Institutions
- University of Minnesota (US)
- Allina Health (US)
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Canadian Journal of Urology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/cju.2025.064710
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00